No, immunotherapy is not exclusively a form of end-of-life or palliative care, though it can be utilized across various stages of cancer progression. It is frequently administered as a front-line primary treatment, adjuvant therapy after surgery, or combination regimen to extend survival, induce long-term remission, and improve quality of life for patients diagnosed with diverse types of advanced or localized malignancies.